Welcome to our dedicated page for Adagio Medical news (Ticker: ADGM), a resource for investors and traders seeking the latest updates and insights on Adagio Medical stock.
Adagio Medical Holdings, Inc. develops catheter-based ablation technologies for the treatment of cardiac arrhythmias. The company’s proprietary Ultra-Low Temperature Ablation technology and vCLAS® Ventricular Ablation System are focused on ventricular arrhythmias, including ventricular tachycardia, using an endocardial approach.
Recurring Adagio Medical news covers FULCRUM-VT clinical updates, FDA IDE activity, planned PMA support, CE Mark-related commercialization outside the United States, next-generation catheter development, pre-clinical publications, medical-conference presentations, financial results, and financing activity tied to its cardiac electrophysiology device programs.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leader in catheter ablation technologies for cardiac arrhythmias, has provided a business update highlighting significant milestones. The company has obtained CE Mark approval and initiated the commercial launch of its vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for ventricular tachycardia (VT) treatment in Europe. Additionally, Adagio has received FDA approval for the FULCRUM-VT Pivotal IDE study in the US, with patient enrollment expected to begin in September.
The company recently closed a business combination with ARYA Sciences Acquisition Corp IV, resulting in its listing on the Nasdaq Capital Market under the ticker symbol 'ADGM'. This transaction, along with concurrent financings, raised approximately $84.2 million, leaving the company with a proforma cash-on-hand of about $35 million after closing.